Non-Small Cell Lung Cancer Equipment
-
Manufactured by Eutilex Co.,Ltd.based in SOUTH KOREA
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T; Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo; Clear anti-cancer efficacy in an orthotopic model; Smaller number of 4th generation GPC3 CAR-T required than other groups to remove ...
-
Manufactured by Lineage Cell Therapeutics, Inc.based in USA
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our pluripotent cell technology using a directed ...
-
Manufactured by Ocean Biomedicalbased in USA
, the tumor suppressor PTEN, and p53. In addition, OCX-253 is a master stimulator of immune checkpoint inhibitor pathways. and plays a critical role in the pathogenesis of primary and metastatic lung cancer. Other disorders for which it shows promise include glioblastoma multiforme and metabolic ...
-
PremiumManufactured by Samyang Corporationbased in SOUTH KOREA
Used to treat breast cancer, non-small-cell lung cancer, prostate cancer, ovarian cancer, head and neck cancer, and esophageal ...
-
PremiumManufactured by Samyang Corporationbased in SOUTH KOREA
Used to treat pleural mesothelioma and non-small-cell lung ...
-
PremiumManufactured by Samyang Corporationbased in SOUTH KOREA
Used as first-line therapy for ovarian cancer or breast cancer or lung ...
-
PremiumManufactured by Samyang Corporationbased in SOUTH KOREA
Used alone or in combination to treat ovarian cancer or breast cancer or lung ...
-
Manufactured by Taiho Oncology, Inc.based in USA
Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations. Non-Small Cell Lung Cancer (Phase 1/2) PHASE ...
-
Manufactured by Boston Pharmaceuticalsbased in USA
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas. ...
-
Manufactured by Eagle Pharmaceuticals, Inc.based in USA
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a single agent for the maintenance treatment of patients with locally advanced or ...
-
Manufactured by Bioceptbased in USA
This kit detects EGFR mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as non-small cell lung ...
-
Manufactured by GeneCentric Therapeutics, Inc.based in USA
GeneCentric has developed two gene expression profilers (LSP 210 and LSP 220) that define molecular subtypes of the two most common forms of non-small cell lung cancer (NSCLC), squamous cell carcinoma, and ...
-
based in SWITZERLAND
Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing ...
-
Manufactured by Shanghai Henlius Biotech, Incbased in CHINA
HANBEITAI (bevacizumab injection) was approved by the NMPA in November 2021. It is indicated for metastatic colorectal cancer (mCRC), advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, cervical cancer, epithelial ovarian ...
-
Manufactured by Rubius Therapeutics, Inc.based in USA
Study Title: Open-label, multicenter, multidose, first-in-human, Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory, or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial ...
-
Manufactured by ViennaLab Diagnostics GmbHbased in AUSTRIA
for clinical trials). Testing of patients with metastatic melanoma or advanced non-small cell lung cancer for BRAF V600 mutations prior to treatment is recommended, as BRAF V600 mutation positive patients may benefit from BRAF inhibitor therapy (e.g. dabrafenib, trametinib, ...
-
Manufactured by Mersana Therapeuticsbased in USA
UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) ...
-
Manufactured by HTG Molecular Diagnostics, Inc.based in USA
The HTG EdgeSeq ALKPlus Assay EU is an in vitro diagnostic (IVD), next-generation sequencing (NGS)-based assay intended to measure and analyze mRNA ALK gene fusion events in formalin-fixed, paraffin-embedded (FFPE) lung tumor specimens from patients previously diagnosed with non-small cell lung ...
-
Manufactured by Gritstone Biobased in USA
of a Phase I/2 clinical study in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer in patients with relevant KRAS mutations who have progressed on prior immunotherapy, and for cancer types where a relevant TP53 mutation ...
-
Manufactured by Elicio Therapeuticsbased in USA
Similar to Kristen rat sarcoma (KRAS), p53 mutations are present in a broad spectrum of cancer types, accounting for approximately 30% of solid tumors. We designed ELI-008 to target p53 hotspot mutations in solid tumor cancers, including melanoma, CRC, and non-small cell lung ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you